ClinicalTrials.gg
Not yet recruitingNCT07575126Updated May 8, 2026

Comparison of Qigong and Otago in Patient With Diabetic Neuropathy

An interventional study of Qigong Balance and Otago Balance in Diabetic Neuropathies, sponsored by Riphah International University. Not yet recruiting at 1 site in Pakistan. Open to participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Diabetic Neuropathies by Riphah International University — 7 open to participants now, 7 under way, none of them phase 3. Diabetic Neuropathies · Riphah International University.

Planned enrollment
12th of 24
44 · median 44
Started
2026
with 3 others
No phase
24 of 24
7 open now
Registered
21st of 24
by date

Among the 24 studies in Diabetic Neuropathies by Riphah International University, this one is the 12th largest by planned enrollment, is one of 4 that started in 2026, is one of 24 with no phase, and was the 21st registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

7 of the 24 studies in Diabetic Neuropathies by Riphah International University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 45 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Diabetic Neuropathies by Riphah International University, or all of them as a file.
02

Study summary

This study seeks to compare these two interventions to better understand their impact on key health outcomes in patients affected by diabetic neuropathy, providing valuable insights for clinicians and healthcare providers managing this challenging condition

03

Conditions studied

  • Diabetic Neuropathies

Browse trials for

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-diagnosed type 2 diabetes without gender bias, with peripheral neuropathy (defined by Michigan Neuropathy Screening Instrument questionnaire score of 5 or greater)
  • Type 2 diabetic peripheral neuropathy patients
  • The ability to walk independently for 10 m
  • Having score between 46 to 52 (out of a total of 56 points) on the BBS

Exclusion criteria

Exclusion Criteria:

  • Fracture of the lower limb within the 6 months before the study (15)
  • Diabetic ulcer, infection or partial amputation in feet (15)
  • Disease or functional impairment of auditory, vestibular system (16)
  • Any other medical conditions that would confound assessment of neuropathy such as , other neurological or orthopedic impairments (such as stroke, poliomyelitis, rheumatoid arthritis, prosthesis, or severe osteoarthritis), major vascular complications (venous or arterial ulcers), severe retinopathy, or severe nephropathy that causes edema or needs hemodialysis (17)
  • Dementia or inability to give consistent information (18)
  • History of surgical procedure at the knee, ankle, or hip or indication of surgery throughout the intervention period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Qigong Balance

    Other: Qigong Balance

  • Active comparator
    Otago Balance

    Other: Otago Balance

Interventions

  • OtherQigong Balance

    Quigong Balance Exercises 3 times per week for 60 minutes per session Open the Flow: Focus on fluid arm movements to enhance relaxation and improve circulation. Shaking Exercise: A full-body shake to release tension and promote energy flow. Lifting the Ball: Alternating arm movements simulating lifting a ball to improve upper body strength and coordination. Playing with Water: Slow, flowing movements that enhance balance and mindfulness. Weight Shifting and Balance Exercises: Stand with feet hip-width apart, shifting weight slowly from one leg to the other, holding each position for 10-15 seconds to engage stabilizing muscles in the legs and improve proprioception. Leg Lifts and Extensions: Perform controlled leg lifts (front, side, and back) to strengthen the quadriceps, hamstrings, and hip abductors.

  • OtherOtago Balance

    Otago (Strengthening) Balance: Sit-to-stand exercises: to improve leg strength. Heel raises: to enhance calf strength. Toe stands: for improving foot stability. Balance Training: Single-leg stands: to enhance balance. Tandem walking: along a straight line. Side leg raises: to strengthen hip muscles 3 times per week for 60 minutes per session

06

What researchers measure

Primary outcomes

  1. Agility T-Test

    The Agility T-Test is a performance-based assessment that measures an individual's agility and ability to change direction quickly. It involves a sequence where the participant runs to a designated point, makes sharp turns around markers in a T-shaped layout, and returns to the starting position.

    Time frame: 12th week

  2. Berg Balance Scale

    is the gold standard test for static and dynamic balance abilities. The BBS is used to measure ability to maintain balance while doing functional task search as reach, standing position and transferences. It is a valid instrument used for the evaluation of effectiveness of interventions with quantitative description of function in clinical practice as well as research. It consists of 14 items including simple balance tasks from everyday life.

    Time frame: 12th week

  3. Functional Reach Test

    FRT is a single item test for dynamic balance and acts as a quick screen for balance problems in older adults. The distance between the lengths of an outstretched arm in a maximal forward reach, while maintaining a fixed base of support is measured. A score of 6 inches or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls. the Functional Reach Test (FRT) demonstrates an ICC of approximately 0.85 to 0.94

    Time frame: 12th week

  4. Gait Speed Test

    The Gait Speed Test measures the time it takes for an individual to walk a specific distance, usually 10 meters, at their usual pace. It has demonstrated strong validity and reliability, with an Intra class Correlation Coefficient (ICC) often exceeding 0.90

    Time frame: 12th week

  5. 10-Meter Walk Test

    The 10-Meter Walk Test involves timing a participant as they walk a distance of 10 meters at their comfortable pace. It assesses gait speed, which is an important indicator of mobility and overall functional ability.

    Time frame: 12th week

07

Study locations

1 site
  • DHQ Gujranwala
    Guiranwala, Punjab Province 54500, Pakistan
    • Javeria Ghazal, MS · Contact+923335154664
    • Junaid Raza, MS · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Aug 2026, 3 months later.

Of 138 non-industry interventional studies with no phase under Diabetic Neuropathies, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's planned 3 months is below that.

Counting every sponsor, half of 153 studies reached it within 11 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
May 8, 2026
StartEst.
May 15, 2026
Primary completionEst.
Aug 15, 2026
CompletionEst.
Aug 30, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07575126
Responsible party
Sponsor
First posted
May 8, 2026
Start date
May 15, 2026 (estimated)
Primary completion
Aug 15, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
May 8, 2026

Study contacts

Muneeb Khan, PhD
Contact
muneeb.khan@riphah.edu.pk
+92336799611
Javeria Ghazal, MS
principal investigator · Riphah International University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion